First PREMIER Bank Sells 4,896 Shares of GlaxoSmithKline plc (GSK)

First PREMIER Bank decreased its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 59.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,391 shares of the pharmaceutical company’s stock after selling 4,896 shares during the period. First PREMIER Bank’s holdings in GlaxoSmithKline were worth $121,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Wealthcare Advisory Partners LLC raised its position in shares of GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the last quarter. FTB Advisors Inc. raised its position in shares of GlaxoSmithKline by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after acquiring an additional 539 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares during the last quarter. Advisory Services Network LLC raised its position in shares of GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after acquiring an additional 788 shares during the last quarter. Finally, Coastline Trust Co bought a new stake in shares of GlaxoSmithKline during the 2nd quarter valued at $202,000. Institutional investors own 9.82% of the company’s stock.

GlaxoSmithKline plc (GSK) traded up $0.44 on Thursday, hitting $36.84. 4,567,386 shares of the company were exchanged, compared to its average volume of 6,198,697. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a market cap of $90,420.00, a PE ratio of 28.78, a P/E/G ratio of 2.15 and a beta of 0.97.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be given a $0.5037 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.47%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is currently 159.38%.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 10.00% of the stock is owned by corporate insiders.

Several analysts have commented on GSK shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday. Investec cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, Bank of America cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. GlaxoSmithKline presently has an average rating of “Hold” and an average price target of $38.57.

TRADEMARK VIOLATION NOTICE: “First PREMIER Bank Sells 4,896 Shares of GlaxoSmithKline plc (GSK)” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://transcriptdaily.com/2018/01/12/first-premier-bank-sells-4896-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply